State Board of Administration of Florida Retirement System Decreases Stock Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

State Board of Administration of Florida Retirement System trimmed its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 6.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 86,193 shares of the life sciences company’s stock after selling 5,832 shares during the quarter. State Board of Administration of Florida Retirement System owned 0.10% of Integra LifeSciences worth $5,902,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Boussard & Gavaudan Investment Management LLP purchased a new stake in shares of Integra LifeSciences during the third quarter valued at approximately $5,004,000. Swiss National Bank increased its position in Integra LifeSciences by 0.4% in the third quarter. Swiss National Bank now owns 158,794 shares of the life sciences company’s stock worth $10,874,000 after buying an additional 700 shares during the last quarter. Duality Advisers LP increased its position in Integra LifeSciences by 133.7% in the third quarter. Duality Advisers LP now owns 30,736 shares of the life sciences company’s stock worth $2,105,000 after buying an additional 17,582 shares during the last quarter. Advisor Group Holdings Inc. increased its position in Integra LifeSciences by 2.4% in the third quarter. Advisor Group Holdings Inc. now owns 7,376 shares of the life sciences company’s stock worth $506,000 after buying an additional 175 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its position in Integra LifeSciences by 2.3% in the third quarter. PNC Financial Services Group Inc. now owns 26,628 shares of the life sciences company’s stock worth $1,825,000 after buying an additional 591 shares during the last quarter. 90.19% of the stock is owned by institutional investors.

Integra LifeSciences stock opened at $68.79 on Friday. Integra LifeSciences Holdings Co. has a one year low of $61.85 and a one year high of $77.40. The business has a fifty day moving average price of $66.95 and a 200-day moving average price of $69.06. The company has a debt-to-equity ratio of 0.92, a current ratio of 3.32 and a quick ratio of 2.33. The firm has a market capitalization of $5.83 billion, a P/E ratio of 27.08, a PEG ratio of 1.50 and a beta of 1.20.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Monday, November 1st. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.72 by $0.14. The company had revenue of $386.86 million during the quarter, compared to analyst estimates of $384.47 million. Integra LifeSciences had a return on equity of 17.33% and a net margin of 14.19%. The firm’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter last year, the company earned $0.80 earnings per share. Sell-side analysts expect that Integra LifeSciences Holdings Co. will post 3.15 earnings per share for the current fiscal year.

In related news, major shareholder Tru St Partnership, L.P. sold 200,000 shares of Integra LifeSciences stock in a transaction on Wednesday, October 20th. The stock was sold at an average price of $69.81, for a total transaction of $13,962,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Glenn Coleman sold 4,275 shares of Integra LifeSciences stock in a transaction dated Tuesday, November 2nd. The stock was sold at an average price of $74.00, for a total value of $316,350.00. The disclosure for this sale can be found here. Insiders have sold 282,725 shares of company stock valued at $19,669,586 in the last three months. 4.20% of the stock is owned by corporate insiders.

A number of research firms have issued reports on IART. JMP Securities reissued a “buy” rating on shares of Integra LifeSciences in a research report on Wednesday, November 3rd. Credit Suisse Group raised their target price on Integra LifeSciences from $84.00 to $87.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 3rd. Finally, JPMorgan Chase & Co. raised Integra LifeSciences from an “underweight” rating to a “neutral” rating and set a $75.00 target price for the company in a research report on Friday, December 17th. Six analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $77.22.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company’s neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices.

Read More: What is FinTech?

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.